ERBB2 and metastatic neoplasm: More recently, the DESTINY-PanTumor02 (NCT04482309) trial evaluated the safety and efficacy of Trastuzumab Deruxtecan (T-DXD), a HER2-directed antibody-drug conjugate (ADC) in patients with HER2-expressing solid tumors with locally advanced or metastatic disease [86].